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Cancer cells evolve in a very complex tumor microenvironment, composed of several cell types, among which the endothelial cells
are the major actors of the tumor angiogenesis. Today, these cells are also characterized for their plasticity, as endothelial cells have
demonstrated their potential to modify their phenotype to diﬀerentiate into mesenchymal cells through the endothelial-to-
mesenchymal transition (EndoMT).*is cellular plasticity is mediated by various stimuli including transforming growth factor-β
(TGF-β) and is modulated dependently of experimental conditions. Recently, emerging evidences have shown that EndoMT is
involved in the development and dissemination of cancer and also in cancer cell to escape from therapeutic treatment. In this
review, we summarize current updates on EndoMTand its main induction pathways. In addition, we discuss the role of EndoMT
in tumorigenesis, metastasis, and its potential implication in cancer therapy resistance.
1. Introduction
Since 2000, with the publication of/e Hallmarks of Cancer
by Hanahan and Weinberg [1], actualized in 2011 [2],
considerable advancements have been done in the un-
derstanding of the biology of cancer. Importantly, a great
eﬀort has been made in the characterization of the micro-
environment where evolve tumor cells. *is microenvi-
ronment is composed of numerous cell types: immune cells
(bone marrow-derived inﬂammatory cells, monocytes/
macrophages, and lymphocytes), vascular cells (endothelial
cells and pericytes), and stromal ﬁbroblastic cells, and of an
extracellular matrix composed of collagen and proteoglycans
[3, 4]. While the importance of the stromal microenvi-
ronment in tumorigenesis has been recognized several de-
cades ago [5], all the properties of the mobilized cells have
not been described so far [6]. Among the cells identiﬁed in
the tumor microenvironment, endothelial cells (ECs) are at
the crossroad of diﬀerent pathophysiological processes in-
volved in tumor growth. *us, since the initial studies
conducted by Folkman [7, 8], numerous works have con-
ﬁrmed and studied the implication of ECs in the process of
angiogenesis that is essential for optimal tumor progression
[9, 10]. Besides their role in angiogenesis involving pro-
liferation, migration, and adhesion, a new concept of en-
dothelial plasticity has emerged last decade, as ECs have
been described as able to modify their phenotype toward a
mesenchymal proﬁle. Initially characterized in physiological
cardiac development, this plasticity is now described in not
only several pathophysiological processes such as cardiac
ﬁbrosis [11], atherosclerosis [12], pulmonary hypertension
[13], and vascular calciﬁcation but also in cancer [14, 15].
Besides this endothelial compartment, cancer-associated
ﬁbroblasts (CAFs) are the most abundant stromal cells in the
tumor microenvironment and are critically involved in
tumor progression. *ey actively interact with neoplastic
cells and form a myoﬁbroblastic microenvironment that
promotes cancer growth and survival and supports malig-
nancy. *us, CAFs aﬀect both the architecture and growth
properties of the developing tumor. CAFs participate in the
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remodeling of peritumoral stroma, which is a prerequisite of
neoplastic cell invasion, expansion, and metastasis. CAFs
may originate from diﬀerent sources (mesenchymal stromal
cells (MSC), normal ﬁbroblasts, and epithelial cells [16]) and
also from ECs [17] through the process of endothelial-to-
mesenchymal transition (EndoMT).
2. Main Features of Endothelial-to-
Mesenchymal Transition (EndoMT)
EndoMT is deﬁned as a cellular transition from an en-
dothelial to a mesenchymal phenotype, owing from the
plasticity potential of ECs. EndoMT was initially observed
in 1975 in the formation of heart valves during embryo-
genesis in vertebrates from a detailed analysis of endo-
cardial cytodiﬀerentiation by transmission electron
microscopy (TEM). In this last study, the authors followed
the cardiac development of rat embryos and observed that,
at E9.5, part of the endocardial cells from the atrioven-
tricular canal and the eﬀerent tract has a particular phe-
notype with morphological alterations such as cellular
hypertrophy, lateralization of the Golgi apparatus, for-
mation of cellular appendages, and loss of cell polarity [18].
*ese previous observations were subsequently conﬁrmed
in a chicken embryo model where the phenotypic change of
cardiac ECs was correlated with new migratory properties
and a concomitant expression of α-smooth actin (α-SMA)
[19].
EndoMT is a transition process where ECs lose their
endothelial characteristic features and acquire mesenchymal
properties [20, 21]. In a similar way as in epithelial-mes-
enchymal transition (EMT), EndoMT is associated with the
gain of mesenchymal markers such as N-cadherin, ﬁbro-
blast-speciﬁc protein-1 (FSP-1), α-SMA, and types I/III
collagen and with the corresponding loss of endothelial
markers such as CD31 or platelet endothelial cell adhesion
molecule 1 (PECAM1), Tie-2, and vascular endothelial (VE)
cadherin [22] (Table 1).
Aside from the acquisition of an activated proﬁbrogenic
phenotype, ECs further lose their apicobasal polarity and
mesenchymal cells acquire new migratory properties. Fur-
thermore, cells in transition have a proinﬂammatory se-
cretory phenotype with increased secretion of cytokines such
as IL-4, -13, -6, -8, and TNF-α, correlated with a synthesis of
extracellular matrix proteins such as ﬁbronectin and col-
lagens [32]. Mechanistically, EndoMT is thought to be in-
stigated by not only inductive signals like TGF-β [33], Wnt/
β-catenin [27], and Notch [34] but also by hypoxia [13] and
oxidative stress [35] (Figure 1).
EndoMT has been characterized in diﬀerent endothelial
human models such as tumor ECs isolated from prostate
cancer [36], normal dermal microvascular endothelial cells
(HDMECs), immortalized dermal microvascular endothelial
HMEC-1 cells [37], human umbilical venous endothelial
cells (HUVECs) [38], or human esophageal microvascular
endothelial cells (HEMEC) [39] treated by TGF-β1 or β-2
or simultaneously by IL-1β and TGF-β2. Moreover, it
has been reported that EndoMT can be induced by epige-
netic modiﬁcations. Recently, in HUVECs, it has been
demonstrated that combined knockdown of two ETS family
transcription factors, ERG and FLI1, induces EndoMT
coupled with dynamic epigenetic changes in ECs [40]. In
these conditions, it has been demonstrated that (i) ECs are
unable to form capillaries in Matrigel® and that (ii) cells notonly lose their endothelial markers and acquire a mesen-
chymal phenotype but also become more invasive with
increasedmigratory abilities [39]. In addition, analysis of cell
proliferation reveals that ECs involved in EndoMT are able
to progress through the cell cycle and that the acquisition of
mesenchymal markers such as α-SMA is independent of cell
cycling [38].
As described above, EndoMT has been conﬁrmed
through various studies conducted on diﬀerent models of
cultured endothelial cells treated by TGF-β1 or -β2. Some
in vivo studies conﬁrmed this process in not only various
physiological situations (development [18, 41] and wound
healing [42]) but also in pathological processes such as
ﬁbrotic diseases [43, 44], pulmonary hypertension [13],
ﬁbrodysplasia ossiﬁcans progressive disease [45], and in
particular in cancer [46, 47]. *e fact that EndoMT is a
progressive, transitional, and complex process makes it
diﬃcult to explore in vivo, especially in ﬁxed tissues.
Nevertheless, EndoMT has been described in human
samples of several pathologies. Detection of stromal cells
coexpressing endothelial and mesenchymal markers was
reported in patients with ﬁbrotic disorders: cardiac ﬁbrosis
[48], radiation-induced rectal ﬁbrosis [49], systemic scle-
rosis [50], and PHA [32]. Up to now, detection of EndoMT
in human cancer patients has been reported in human
colorectal tissue sections [51]. In vivo evidence of EndoMT
has been rendered possible through the use of genetic
lineage tracing technology, enabling to follow EC lineage
conversion in vivo [52]. Use of Cre-LoxP-mediated en-
dothelial tracing under the endothelial speciﬁc promoter
(Tie-2 or Cdh5) has been used to develop animal models
suitable for studying endothelial-to-mesenchymal transi-
tion. In non-cancerous pathologies, this strategy has been
successful to show an EndoMTprocess in cardiac [53] and
kidney [54, 55] ﬁbrosis, in vein graft remodeling [56]. *e
endothelial origin of 40% of CAF has been demonstrated in
a model of subcutaneous melanoma in Tie-2-Cre ×
R26TRosa Lox-stop-LacZ crossed mice [17]. Animal
studies through endothelial-speciﬁc targeting revealed also
the role of p53 in radiation-induced EndoMT in a pul-
monary adenocarcinoma model [57]. In addition, in the
murine pancreatic cancer model Rip-Tag2, absence of
CD105/endoglin in ECs favored an EndoMT process [58].
3. EndoMT: A Transition Process with
Heterogeneous Regulation
In vitro studies have provided a better understanding of
phenotypic alterations of ECs during EndoMTand have also
shown speciﬁcity of response depending on the experi-
mental conditions. *us, the expression of the mesenchymal
proteins depends on (i) the nature of the inducing agent,
(ii) the tissue origin of ECs [59], (iii) the signaling
pathway(s) mobilized [60], and (iv) the cytokinic
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composition of the microenvironment [61]. Some studies
suggested that the stability of the mesenchymal phenotype
depends on the duration of EC stimulation by various
stimuli (TGF-β1, IL-1β, and TNF-α) [62, 63]. In human
intestinal microvascular endothelial cells (HIMEC)
treated simultaneously by TGF-β, TNF-α, and IL-1β,
EndoMTappeared completed at 6 days and was prolonged
up to 10 days, suggesting then the creation of a stable
mesenchymal phenotype [64]. *e nature of the extra-
cellular matrix also appears as a determining parameter in
the induction of EndoMT, as in vitro experiments have
demonstrated a signiﬁcant increase in mesenchymal
α-SMA expression in ECs cultured on an enriched-ﬁ-
bronectin matrix, but not on the collagen- or gelatin-
matrix [43, 65]. *ese data suggest that the nature of the
microenvironment matrix inﬂuences the induction of
EndoMT and could play a key role in the development of
diseases such as ﬁbrosis or cancer [66].
*e notion of reversibility/irreversibility has been
suggested and evidenced for the epithelial-to-mesen-
chymal transition (EMT). EMT is reversed by Twist gene
silencing [67]. Furthermore, hypoxia-induced EMT in
MDA-MB-231 breast cancer cells may be reversed not
only by reoxygenation, providing a model for changes that
may occur in vivo when cancer cells intravasate into the
bloodstream or metastasize to the lungs, but also by si-
lencing µPA expression that decreased expression
of Vimentin and Snail [68]. Similarly, in Madin–Darby
canine epithelial cells, it has been found that Snail
overexpression induced EMT, while Snail silencing
upregulated epithelial markers and downregulated mes-
enchymal markers conﬁrming the reversibility of EMT
[69]. Taken together, these ﬁndings suggest that EndoMT
could also be reversible, especially since the mediators
mobilized during one and the other of the processes are
identical.
*us, the stability and the reversibility of the mesen-
chymal phenotype, issued from EndoMT, have been studied
in vitro by analyzing the evolution of the protein signature
after several days of culture in the presence of various stimuli
(TGF-β1, IL-1β, and TNF-α) [62, 63, 70].
Furthermore, diﬀerent in vitro studies showed that
EndoMT is initiated from the ﬁrst six hours after stimulation
and that this process could be reversible for culture times less
than 10 days in the presence of proinﬂammatory cytokines
as TGF-β1. Furthermore, when EC are treated with cyto-
kines for a period of 20 days, the acquisition of the mes-
enchymal phenotype is stable over time and irreversible
[44, 64].
While partial EMT is well described in the literature,
partial EndoMT is, to date, little studied although it
constitutes an emerging concept in the ﬁeld of oncology.
Welch-Reardon et al. were the ﬁrst to suggest this concept
by comparing angiogenesis to EndoMT and then by
identifying several similarities [71]. Among these, the tip
cells that lead emerging sprouts lack apical-basal polarity,
degrade the extracellular matrix, and, by deﬁnition, are
migratory. Moreover, angiogenic ECs do not usually
separate from their neighbors and express signiﬁcantly
Slug, a Snail family of zinc-ﬁnger transcription factor [71],
suggesting that angiogenesis may involve a partial
EndoMT [46]. *ese data have been conﬁrmed in an
adenomyosis model in which it has been found that its
development is associated with a signiﬁcant angiogenesis
induced by estrogen and dependent on the activation of
the Slug-VEGF axis [72]. Finally, more recently, it has
been reported, in a model of ovarian carcinoma, that the
inhibition of Slug expression decreased signiﬁcantly the
growth of tumor and microvessel density [73]. Taken
together, these ﬁndings suggest that the same mediators or
the same signaling pathways that induce EMT or angio-
genesis may also drive ECs toward a mesenchymal phe-
notype that could be also associated with metastasis.
Angiogenesis could represent a partial EndoMT, and we
therefore believe that anti-angiogenic drugs may have a
dual beneﬁt for treating metastatic cancers, as they could
Table 1: Comparison of main features during EMT and EndoMT.
EMT EndoMT
Cells Epithelial cells Endothelial cells
Induction mediators TGF-β [23], Wnt/β-catenin [24], Notch [25] TGF-β [26], Wnt/β-catenin [27],hypoxia [13], oxidative stress [28], Notch [29]
Epithelial/endothelial markers E-cadherin, N-cadherin [30, 31] VE cadherin, CD31/PECAM-1, vWF
Mesenchymal markers α-SMA, FSP-1, vimentin
Transcription factors Slug, Snail-1 and -2, Twist
TGF-β
Wnt/β-catenin
ROS
Hypoxia
Notch
EndoMT
Slug
Snail-1 and -2
Twist
Endothelial cells
Mesenchymal cells
FSP-1
α-SMA
Vimentin
Snail
Twist
VE-cadherin
CD31/PECAM-1
vWF
Tie-2
β-Catenin
Figure 1: Phenotypic modiﬁcations during EndoMT. TGF-β
(transforming growth factor-β); ROS (reactive oxygen species); VE
cadherin (vascular endothelial cadherin); vWF (vonWillebrand
factor); FSP-1 (ﬁbroblast-speciﬁc protein-1); α-SMA (α-smooth
muscle actin).
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delay metastatic development by inhibiting both angio-
genesis and EndoMT.
In summary, EndoMT is characterized by a permanent
alteration of the endothelial phenotype evolving toward a
mesenchymal phenotype. Speciﬁcity of the mesenchymal
markers acquired during this transition appears to be de-
pendent not only on the nature of the inducing agents
present in the microenvironment but also on the tissue
origin of the EC.*e reversion of this process may also occur
during a short time after its initiation [74], but the acqui-
sition of the mesenchymal phenotype appears stable in a
context of chronic induction, as it might be the case in
cancer for example.
4. Main Signaling Pathways
Involved in EndoMT
*e TGF-β family of proteins comprises several pleiotropic
growth factors that play crucial roles in numerous physio-
logical processes including embryogenesis, cellular develop-
ment and diﬀerentiation, immunologic system development,
inﬂammatory response functions, and wound repair. *e
TGF-β superfamily consists of four major subfamilies: the
TGF-β subfamily, the bone morphogenetic proteins (BMP),
the activin and inhibin subfamilies, and a group encom-
passing various divergent members [75]. TGF-β1, -β2, and
-β3 are three distinct isoforms, which have been extensively
found in mammal tissues. TGF-β signals through TGF-β
receptors (TβRs) I and II to activate downstream signaling
pathways [76]. In the absence of ligand, TβRI and TβRII exist
as monomers, homodimers, or heterodimers on the cell
surface. Ligand binding promotes formation of a tetrameric
complex between TβRII dimers and two TβRIs. TGF-β binds
speciﬁcally to the constitutively active TβRII, which activates
TβRI by phosphorylating the glycine/serine-rich domain.
Activated TβRI then phosphorylates downstream eﬀectors to
induce signal transduction [77]. Induction of EndoMT
through TGF-β seems to involve two distinct signaling
pathways: (i) one leading to an increase of Snail-1, one of the
main transcription factors that regulate EndoMT together
with Slug and Twist, and (ii) one recruiting the Smad
pathways [78]. Furthermore, TGF-β signals through both
canonical Smad-dependent and non-canonical Smad-in-
dependent pathways. Considering the canonical pathway,
following ligand binding, the type II receptor phosphorylates
the type I receptor, which in turn phosphorylates the re-
ceptor-regulated Smads (R-Smads) (Smad-2 and -3). When
activated, R-Smads associate with Smad-4, a common-partner
Smad (Co-Smad), and translocate to the nucleus to control
the transcription of the target gene [79]. Smad-7 acts as a
negative feedback and regulates Smad signaling by
forming a stable complex with type I receptors, therefore
leading to inhibition of R-Smad phosphorylation and the
heterocomplex formation between R-Smads and Co-Smad
[79]. *is heterocomplex translocates into the nucleus,
where it regulates the transcription of target genes [80],
among which are the diﬀerentiation transcription factors
Snail, Twist, and Slug.
In addition to this canonical pathway, TGF-β isoforms
are also able to activate Smad independent or non-canonical
pathways, including mitogen-activated protein kinases and
phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling
pathways [81]. Indeed, TGF-β signaling also activates nu-
merous serine/threonine kinases that phosphorylate Smad-2
in its linker region. Interestingly, in primary-cultured bovine
aortic ECs, it has been reported that TGF-β-mediated
phosphorylation of individual serine/threonine sites in the
linker region of Smad-2 occurs in a highly speciﬁc manner
by kinases [82] (Figure 2).
TGF-β is considered the most important regulator of
both EMT in cancer [83] and EndoMT in cardiovascular
development [84] or disease as well as in cancer [60, 84].
However, it appears that the three isoforms of TGF-β did not
have the same eﬃcacy to induce EndoMT, according to the
tissue origin of the EC and to the pathophysiological context
(heart development, ﬁbrosis, and cancer). TGF-β1 has been
ﬁrstly reported to be the main and unique regulator of
EndoMT in a mouse atriovascular canal (AVC) model [85],
while TGF-β2 and TGF-β3 were shown to cooperate to
mediate EndoMT in cultured chick AVC explant cells. In
this study, it has been also reported that TGF-β2 mediates
initial endothelial cell-cell separation, while TGF-β3 is re-
quired for the cell morphological change that enables the
migration of cells into the underlying extracellular matrix
[21]. Of the diﬀerent isoforms of TGF-β, TGF-β2 appeared
to be the one that induced EndoMT. *us, in diﬀerent EC
models including the mouse pancreatic microvascular en-
dothelial cells (MS-1), it has been noted that activation of
Smad signals by TGF-β2 has dual eﬀects on the activation of
Rho signals and myocardin-related transcription factor-A
(MRTF-A), leading to the mesenchymal transition of MS-1
endothelial cells [86].
Recent studies have investigated the dose eﬀect of TGF-
β1, TGF-β2, and TGF-β3 on the induction of EndoMT in
invasive colon cancer and have shown that TGF-β2, by
increasing the expression of mesenchymal markers
N-cadherin and α-SMA, is the most potent inducer of
EndoMT in this model [87]. *ese ﬁndings have been
conﬁrmed in endothelial cells HMEC-1 grown in condi-
tioned media from invasive colon cells. An increased pro-
duction of TGF-β1 correlates with a signiﬁcant EndoMTand
is associated with an increase of β3-tubulin expression and
phosphorylation [87]. Furthermore, it has also been high-
lighted that TGF-β1- and TGF-β3-induced EndoMT re-
quires a paracrine loop involving TGF-β2 [88].
Concerning the non-canonical pathway or Smad-in-
dependent pathway, TGF-β2 has been shown to activate PI3K/
Akt/mTOR, ERK 1/2, and P38 MAPK pathways. *ese sig-
naling pathways appear then necessary to promote the in-
creased expression of transcription factor Snail [78]. *is
direct regulation of Snail by TGF-β2 has been highlighted in a
study conducted on mouse embryonic stem cell-derived en-
dothelial cells (MESECs), where TGF-β2-induced EndoMT,
characterized by a decrease in the expression of the endothelial
marker claudin 5 and an increase in expression of the mes-
enchymal α-SMA [89].
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Snail is described as one of the major transcription
factors involved in cell plasticity, suppressing cell adhesion
and promoting EMT [90, 91]. Interestingly, studies have
shown that overexpression of Snail in cells is suﬃcient to
induce EMT. If Snail alone is able to induce EMT, addi-
tional mechanisms are involved to mediate change in
endothelial morphology in the case of EndoMT. One of
them relies on the inhibition of GSK-3β. *is protein was
identiﬁed as a regulator of Snail activity in TGF-β2-in-
duced-EndoMT [78]. Snail protein stability and nuclear
translocation are inhibited through phosphorylation by
GSK-3β [92]. In human cardiac endothelial cells
(HCMECs), it has been shown that inhibition of GSK-3β
by TGF-β2-induced PI3K signaling allows Snail to induce
EndoMT by transcriptional modulation. PI3K is also
necessary for controlling Snail gene expression, demon-
strating a dual role for this pathway in mediating EndoMT
[78].
Hypoxia has also been described as a potent inducer of
EndoMT. HIF-1, the main eﬀector of the hypoxia path-
way, is responsible for driving the expression of VEGF-A
to promote angiogenesis. Previous research has identiﬁed
an active hypoxia response element (HRE) within the
VEGF promoter and implicated that TGF-β can cooperate
with hypoxia to enhance VEGF transcription [93], pro-
viding some of the ﬁrst evidence that these two factors can
work together to drive angiogenesis. In addition, several
studies suggest that hypoxia regulates the expression of
TGF-β1, -2, and -3 [94–96]. Finally, hypoxia also induces
the expression of EndoMT-associated transcription factor
Snail and Slug [97]. Both of these factors are induced by
TGF-β in ECs [98] and were demonstrated to drive
EndoMT associated with the sprouting phase of angio-
genesis [71].
*e Wnt/β-catenin canonical pathway is another stim-
ulus for inducing EndoMT [33, 99]. Wnt signaling is a
complex collection of signal transduction pathways medi-
ated by multiple signaling molecules and is critically im-
portant for developmental processes, including cell
proliferation, diﬀerentiation, and tissue patterning [100].
Wnt signaling activates cytoplasmic eﬀectors and reg-
ulates the transcription of target genes (Figure 3). β-Catenin
is a downstream eﬀector of the Wnt signaling that accu-
mulates in the cytoplasm and eventually translocates into the
nucleus to act as a transcriptional coactivator for TCF/LEF
transcription factors family members [101]. While the
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Figure 2: Transforming growth factor-β- (TGF-β-) induced EndoMT. Upon stimulation by TGF-β1, -2, or -3, type-2 TGF-β receptors
phosphorylate ALK5 (type-1 TGF-B receptor) and associate into a heterotetrameric structure which induce Smad-2/3/4 complex formation
and translocation to the nucleus. Stimulation by TGF-β1 or -3 induces a paracrine loop toward a TGF-β2 stimulation. Smad-7 acts as an
inhibitor of Smad association and serves as a negative retro control. TGF-β signaling also induces phosphorylation of ERK 1/2 (extracellular
signal-regulated kinases 1/2) and p38 MAPK (p38 mitogen-activated protein kinase). *e BMP receptors can also trigger upon stimulation
by the BMP ligand canonical Smad pathway and non-canonical ERK pathway. Inside the nucleus, all actors involved stimulate the activity of
the transcription factor, mainly Snail, Slug, and Twist, thus initiating EndoMT by promoting transcription of mesenchymal markers and
diminishing transcription of endothelial markers. TGF-β signaling crosstalk with several others pathways, including Notch which promotes
ERK 1/2 activity and Akt2 isoform activity which will then inhibit GSK-3β. GSK-3β, ERK, PI3K, P38, and also CDK4 can phosphorylate
Smad-2 and -3 on speciﬁc residues in its linker region (in red) promoting Smad signaling in a canonical-independent manner. However, it is
worth to note that some studies report the inhibiting eﬀect of linker region phosphorylation, and that the speciﬁc eﬀects of this phos-
phorylation site seem to be cell-type dependent.
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detailed molecular events and signaling pathways initiating
EndoMT have not been clearly elucidated, this canonical
β-catenin-dependent Wnt pathway has been found to be
involved in EndoMT in both myocardial infarction [99, 102]
and in oral squamous cell carcinoma [103].
Reactive oxygen species (ROS) have emerged as an
important factor aﬀecting several cancer hallmarks [104].
ROS are involved in the acquisition of self-suﬃciency in
proliferation signals and in the development of a more
aggressive phenotype through matrix metalloproteinase
(MMP) secretion and regulation of cellular plasticity. *e
ROS family includes several molecules, such as hydroxyl
radical (·OH), superoxide radical (O2−), hydrogen peroxide
(H2O2), and peroxynitrite (OONO−), which are produced by
normal and pathogenic oxygen metabolism. Several studies
have evaluated the role of oxidative stress in the control of
EndoMT in endothelial dysfunction [105], atherosclerosis
[70], or renal failure secondary to renal ischemia [106].
Treatment with 0.1 to 10 μMH2O2 triggered the trans-
formation process in primary EC, as observed by changes in
endothelial and mesenchymal markers expression. *is ef-
fect is mediated by TGF-β1 secretion and is dependent on
Smad-3 activation [105]. Furthermore, it has been reported
in HUVEC treated by TGF-β1 that inhibition of oxidative
stress by kallistatin, a plasma protein distributed in blood
vessels, is correlated with a signiﬁcant decrease of EndoMT
[35]. In the context of massive oxidative stress such as tissue
exposure to ionizing radiation, it has been established that
irradiated intestinal endothelial cells undergo endothelial-
to-mesenchymal transition. *erefore, radiation-induced
EndoMT participates in radiotherapy-induced gut damage
such as proctitis [49]. While these ﬁndings conﬁrmed a main
role of ROS to induce EndoMT in ECs, little is known about
the actual impact of oxidative stress in triggering EndoMTin
cancer. However, cancer-associated ﬁbroblasts (CAFs)
issued from EndoMT could be important intermediaries
through their capacity to signiﬁcantly produce ROS [107].
Indeed, because ROS are hallmarks of inﬂammation, known
as a common state in tumoral stroma, we can hypothesize a
strong link between ROS and EndoMT in the context of
cancer.
Taken together, the studies presented in this review
clearly illustrate the participation of diﬀerent signaling
pathways in the modulation of EndoMT. However, it is not
excluded that other mediators could also be involved.
Among these, Notch was identiﬁed in EndoMTobserved in
the cardiovascular pathophysiological context. Notch is
deﬁned as a transmembrane receptor and a transcription
factor [108]. *e Notch signaling is an evolutionary con-
served pathway that plays an essential role in both in-
vertebrates and vertebrates, by controlling cellular fate, cell
growth, and diﬀerentiation. Notch signaling is pleiotropic,
inﬂuencing embryogenesis, diﬀerentiation, and homeostasis
in adult tissue, and it contributes to the plasticity and
functionality of diﬀerent cell types. Perturbations in the
Notch signaling pathway have been associated with various
genetic disorders and cancers [109]. *e role of Notch in the
control of EndoMT has been mainly shown during heart
valves development, arterial-venous diﬀerentiation, and
remodeling of the primitive vascular plexus [29]. In the
embryonic heart, Notch has been identiﬁed to promote a
TGF-β-mediated EndoMT that leads to development of
cardiac valvular. *is process is explained by an induction of
Snail-1 expression and activity and a downregulation of VE
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cadherin expression [110]. *is TGF-β/Notch link has been
conﬁrmed in an aortic EC model as active Notch expression
promotes EndoMT, resulting in downregulation of VE
cadherin and upregulation of mesenchymal genes such as
those for ﬁbronectin and Snail-1/2. Furthermore, TGF-β1
was reported to exacerbate Notch eﬀects by increasing Snail-1
and ﬁbronectin activation [111] (Figure 4). Furthermore, the
endothelial overexpression of the transcription factor Hey-2, a
well-known Notch eﬀector, has been shown to induce
EndoMT in a preclinical model of radiation-induced proctitis
[112].
Few studies have assessed the role of Notch in EndoMT
during tumorigenesis.*us, from a xenograft tumor assay of
two breast tumor cell linesMDA-MB231 orMCF-7 in NOD/
SCID mice, an education of EC by tumors cells through a
crosstalk between Notch and TGF-β pathways has been
reported. *is cooperation generated the formation of a
transient mesenchymal/endothelial niche, associated with a
signiﬁcant increase in tumor proliferation, stemness, and
invasiveness [113].
5. EndoMT: A Pathophysiological Process
Promoting Tumorigenesis
*e process of EndoMT initially described in physiological
cardiac development has also been identiﬁed in the
pathological context of cardiac and pulmonary ﬁbrosis
[11], atherosclerosis [12], and vascular calciﬁcation [114].
Furthermore, increasing evidence implies the process of
EndoMT in the context of cancer as a relevant contributor
of the tumor microenvironment plasticity.
5.1. EndoMT and Cancer-Associated Fibroblasts (CAFs).
It is clearly established that ECs through the EndoMT
process is an important source of CAFs. In vivo, use of the
gold standard strategy to explore cell lineage conversion,
namely, the Cre-LoxP genetic lineage labeling system
technology [52], allowed to prove that up to 40% of CAF in
pancreas cancer or melanoma model [17] results from
EndoMT [46]. *ese cells are known to facilitate cancer
progression [17, 37]. CAFs are now identiﬁed as the major
contributor to tumor growth and metastatic dissemination
[77], mainly through their secretome and release of classical
growth factors and chemokines shown to inﬂuence diﬀerent
aspects of tumor cell behavior [115]. CAFs issued from
EndoMT acquire their activated state and maintain it by
various mechanisms including genetic or epigenetic muta-
tions or under the persistent eﬀect of growth factors or
speciﬁc cytokines produced by tumor microenvironment
[79].
During primary cancer progression, CAFs communi-
cate with cancer cells through the secretion of growth
factors, chemokines, and cytokines. For instance, CAF-
derived TGF-β, epidermal growth factor (EGF), ﬁbroblast
growth factor (FGF), vascular endothelial growth factor
(VEGF), and matrix metalloproteinase (MMP) have been
implicated in epithelial cancer progression [116, 117].
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Furthermore, CAFs are able to provide potential oncogenic
signals: (i) CAF-derived TGF-β participates in acceleration
of cancer cell invasion, and (ii) CAF-derived growth factors
and angiogenic factor VEGF can stimulate cancer pro-
gression, including angiogenesis [118]. More recently, the
role of CAF in tumor angiogenesis has been described in a
C8161-HA mouse melanoma model. In this study, the
authors established a link between tumor development and
inhibition of SERPIN F1 production by activated ﬁbro-
blasts from tumor microenvironment.*is latest inhibition
was associated with an increase of angiogenesis and a
strong expression of proangiogenic factors [119].
5.2. EndoMT and Extravasation of Tumor Cells. Evidence
suggests that ECs are not passive actors during trans-
endothelial migration of cancer cells, as this passage re-
quires profound changes in endothelial junctional protein
expression, signaling, permeability, and contractility.
EndoMT leads to a deep reorganization of microvessels
with a cytoskeletal remodeling, an increase in endothelial
barrier permeability linked to loss of adhesion molecules
(claudins and VE-cadherin). *is active process in the
endothelial compartment is compatible with the extrava-
sation of cancer cells, which is the ﬁrst step of the metastatic
process [120]. *is hypothesis has been conﬁrmed in a
study which evaluated the role of EndoMT induced by
TGF-β1 on various ECs (brain endothelial cells and
HUVEC) during melanoma metastatic extravasation.
Stimulation of ECs with activated cancer cell line-condi-
tioned medium resulted in TGF-β-dependent decrease of
transendothelial electrical resistance (TEER), increase in
adhesion between metastatic and ECs, and enhanced
transendothelial migration of melanoma cells. *ese
ﬁndings suggested that EndoMT may be necessary for an
optimal metastatic transendothelial migration and may be
one of the potential mechanisms occurring during the
complex phenomenon of metastatic extravasation [121].
6. EndoMT and Response to Therapies
As described in this review, EndoMT is found in tumors and
is mainly induced by factors issued from the tumor itself or
from its educated microenvironment, such as TGF-β. *is
phenotypic transition is a unique source of CAFs [17] and
may also be part of a facilitated extravasation of cancer cells
into the blood circulation [121]. Cancer therapies may also
be regulating factors of EndoMT. Histone-deacetylase
HDAC inhibitor valproic acid, currently under clinical in-
vestigation for anticancer therapy, has recently been shown
to induce EndoMT via a TGF-β1 signaling pathway [15]. On
the contrary, a conjugate of temozolomide and perillyl al-
cohol, used in a glioblastoma model, inhibits EndoMT and
reverts the mesenchymal phenotype of tumor-associated
brain EC [122]. Exposure to ionizing radiation also leads to a
phenotypic conversion of EC in the colon and lung carci-
noma preclinical models [57] but also in normal rectal
tissues, leading then to radiation-induced ﬁbrosis [49]. In-
creasing evidence highlights the importance of EndoMT in
tumor progression, favoring metastasis and being an im-
portant source of CAFs. Furthermore, the role of EndoMTin
cancer resistance to therapies appears as a novel emerging
ﬁeld with scarce but exciting studies. As mentioned above,
radiation induces EndoMT that awakes dormant cancer
stem cells from hypoxic regions and polarizes tumor-as-
sociated macrophages TAM toward an M2 phenotype,
therefore conferring tumor radio-resistance and promoting
tumor progression [57]. Resistance to chemotherapies cis-
platin and geﬁtinib in a multicellular lung tumor spheroid
model is alleviated when EndoMT in ECs in the spheroid is
reversed, implying EndoMT as a resistance factor [123]. In
an invasive colon cancer model, EndoMT culminates in the
generation of CAF-overexpressing tubulin-3, a known factor
of resistance to taxanes-type of chemotherapeutics [87]. *e
resulting cells of the EndoMTprocess, namely, the CAF, are
well described for their roles in cancer resistance, recently
reviewed [16]: they produce soluble factors (IL-6 and IL-8)
associated with chemiresistance, and they can control
chemotherapy uptake either by reducing expression of drug
transporters or by trapping active drugs, limiting their
availability to the tumor. CAFs are also known to limit
oxidative stress-induced by chemotherapy and therefore to
protect the tumor cell from ROS-induced apoptosis. Fur-
thermore, in breast and lung cancers, CAFs have been shown
to sustain cancer stemness, by promoting a survival niche for
cancer stem cells [124]. Several studies reinforce this notion
of a link between EndoMTand stemness. Indeed, radiation-
induced EndoMT has been shown to reactivate dormant
cancer stem cells CD44v6+, driving then tumor regrowth
[57]. In a non-tumoral model of pulmonary arterial hy-
pertension (PHA), that share similarities with carcinogen-
esis (excessive proliferation, apoptotic resistance, and
inﬂammation), expression of the stemness marker CD44v is
induced in pulmonary EC undergoing EndoMT and is as-
sociated with the increased level of antioxidant GSH mol-
ecules [125]. Analogy between PAH and carcinoma suggests
that EndoMT could favor survival of either mesenchymal
cells (PHA) or tumor cells (carcinoma) in condition of
important oxidative stress such as that induced by che-
motherapy and radiotherapy. Several works pointed that
EndoMT could also induce an abnormal recruitment of
pericytes [57] and could give rise to pericyte-like cells within
the tumor and abnormally cover the vasculature [58]. *ese
populations of pericytes have been proposed as a signature of
tumors refractory to anti-VEGF therapy in at least two
diﬀerent cancer models (pancreas [126] and melanoma
[127]), highlighting an implication of EndoMT in tumor
stromal resistance. *e role of EndoMT needs to be deeply
explored and fully understood as this process of cellular
plasticity could be envisaged in a close future as the ther-
apeutic strategy.
7. Conclusion
Taken together, the studies presented in this review clearly
identify plasticity of ECs as a pillar of tumor development
through modiﬁcation of their phenotype. *is plasticity is
involved in tumorigenesis and metastatic progression and
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appears relevant in resistance therapy. Evidence suggests the
existence of a complex signaling network involving TGF-β,
Wnt/β-catenin, and Notch pathways that mediate and
control EndoMT. *e complexity of these pathways and
their potential interconnections suggest that further studies
are necessary to better understand their roles in EndoMT in
both animal tumor models and in human cancer. *us,
future eﬀorts should be devoted to the exploration of mo-
lecular mechanisms involved in this process. *ese eﬀorts
would eventually lead to the development of novel thera-
peutic approaches, targeting this microenvironmental
plasticity to improve tumor treatment and limit metastatic
dissemination and resistance to various anti-tumor
therapies.
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